Articles

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Memorial Sloan Kettering Cancer Center, New York, NY
Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA/US Oncology Research, US Oncology Network, Texas
Genentech, Inc., South San Francisco, CA
Genentech, Inc., South San Francisco, CA
Genentech, Inc., South San Francisco, CA
AbbVie, North Chicago, IL
Roche Products Limited, Welwyn Garden City
Roche Products Limited, Welwyn Garden City
Genentech, Inc., South San Francisco, CA
Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC
Haematologica Early view Dec 17, 2020 https://doi.org/10.3324/haematol.2020.266486